1

Creates new platform for 

sustainable growth further

increasing our biotech exposure

Expands footprint in attractive,

growing rare disease market

Increases our U.S. presence and

expands our R&D pipeline of Phase

II and Phase III products

Meets sanofi-aventis value creation

criteria

Preserves strong capital structure

and financial strength

1

Sanofi-aventis

Acquisition

of

Genzyme

Would

be

Beneficial for Both Parties

Provides immediate value for all

shareholders

Captures the potential of

Genzyme’s

business and pipeline

and shifts execution risk to sanofi-

aventis

Enhances Genzyme’s

rare disease

business as a center of excellence

Creates more value for Genzyme’s

other product lines within a larger

company with global reach and

resources

Exhibit (a)(5)(k)